ClinicalTrials.gg
Active, not recruitingNCT07514260Updated Nov 9, 2026

A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.

A Phase 1 interventional study of ABBV-295 and Placebo for ABBV-295 in Healthy Volunteer, sponsored by AbbVie. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by AbbVie · Phase 1, Interventional, and Basic science

Updated Nov 9, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to assess the adverse events, tolerability, and Pharmacokinetics (PK) of subcutaneous injections of ABBV-295 in healthy adult Japanese participants with overweight or obesity.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • Healthy Volunteer
  • ABBV-295
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 9, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese participant must be first-or second-or third-generation Japanese of full Japanese parentage.

    1. First-generation participants must have two parents and four grandparents of full Japanese descent.
    2. Second-or third-generation participants born outside of Japan must have two parents and four grandparents of full Japanese descent.
  • is ≥ 25.0 to ≤ 35.0 kg/m2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.

Exclusion criteria

Exclusion Criteria:

  • Participant has a self-reported change in body weight ≥ 5% within 3 months prior to Screening.
  • ≥ 6.5% and/or serum glucose ≥ 126 mg/dL at Screening.
  • Participant has taken a medication for the purpose of treating obesity (e.g. Glucagon-like peptide-(GLP-1) agonists, GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonists, bupropion-naltrexone, orlistat, metformin, phentermine-topiramate, amphetamine-based stimulants, methylphenidate) or has been enrolled in an obesity trial within 180 days prior to study treatment administration.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    ABBV-295 Part 1

    Participants will receive subcutaneous doses of ABBV-295 for 12 weeks.

    Drug: ABBV-295

  • Experimental
    Placebo for ABBV-295 Part 1

    Participants will receive subcutaneous doses of placebo for 12 weeks.

    Drug: Placebo for ABBV-295

  • Experimental
    ABBV-295 Part 2

    Participants will receive subcutaneous doses of ABBV-295 for 13 weeks.

    Drug: ABBV-295

  • Experimental
    Placebo for ABBV-295 Part 2

    Participants will receive subcutaneous doses of placebo for 13 weeks.

    Drug: Placebo for ABBV-295

Interventions

  • Subcutaneous Injections

  • DrugPlacebo for ABBV-295

    Subcutaneous Injections

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.

    Time frame: Up to approximately 145 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Jan 2027 → Dec 2026 and completion Jan 2027 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2026
First posted
Apr 7, 2026
StartActual
Mar 31, 2026
Primary completionEst.
Dec 2026was Jan 2027
CompletionEst.
Dec 2026was Jan 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jan 2027→Dec 2026
Nov 9, 2026
Study completion
Jan 2027→Dec 2026
Nov 9, 2026
Eligibility
4 inclusion criteria edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedJapanese participant must be first-or second-or third-generation Japanese of full Japanese parentage.
  • EditedFirst-generation participants willmust have been born in Japan to two parents and four grandparents also born in Japan of full Japanese descent.
  • EditedSecond-or third-generation participants born outside of Japan must have two parents and four grandparents born in Japan of full Japanese descent.
  • EditedBMI is ≥ 2325.0 to ≤ 35.0 kg/m2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.
Exclusion criteria
  • EditedParticipant has taken a medication for the purpose of treating obesity (e.g. Glucagon-like peptide-1, (GLP-1) agonists, Glucagon-like peptideGLP-1/glucose-dependent insulinotropic polypeptide (GLP-1/GIP) agonists, bupropion-naltrexone, orlistat, metformin, phentermine-topiramate, amphetamine -based stimulants, methylphenidate) or has been enrolled in an obesity trial within 180 days prior to study treatment administration.
Nov 9, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameNumber of Participants with Adverse Events (AEs)Up to approximately 138 days → Up to approximately 145 days
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Primary completion Jan 2027→Dec 2026
    Study completion Jan 2027→Dec 2026
    Eligibility 4 inclusion criteria edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedJapanese participant must be first-or second-or third-generation Japanese of full Japanese parentage.
    • EditedFirst-generation participants willmust have been born in Japan to two parents and four grandparents also born in Japan of full Japanese descent.
    • EditedSecond-or third-generation participants born outside of Japan must have two parents and four grandparents born in Japan of full Japanese descent.
    • EditedBMI is ≥ 2325.0 to ≤ 35.0 kg/m2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.
    Exclusion criteria
    • EditedParticipant has taken a medication for the purpose of treating obesity (e.g. Glucagon-like peptide-1, (GLP-1) agonists, Glucagon-like peptideGLP-1/glucose-dependent insulinotropic polypeptide (GLP-1/GIP) agonists, bupropion-naltrexone, orlistat, metformin, phentermine-topiramate, amphetamine -based stimulants, methylphenidate) or has been enrolled in an obesity trial within 180 days prior to study treatment administration.
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameNumber of Participants with Adverse Events (AEs)Up to approximately 138 days → Up to approximately 145 days
    + 2 other changes: verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07514260
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Apr 7, 2026
Start date
Mar 31, 2026
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 9, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABBV-295

Start the discussion